Y-mAbs Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Y-mAbs Therapeutics

29/02/2024 22:02

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported a quarterly
adjusted
loss of 2 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of 3 cents.  The mean expectation of six analysts for the
quarter was for a loss of 20 cents per share. Wall Street
expected results to range from -24 cents to -16 cents per share.
    * Revenue fell 25.7% to $23.36 million from a year ago;
analysts
expected $20.95 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 2 cents​.
    * The company reported a quarterly loss of $988 thousand.
    * Y-mAbs Therapeutics Inc shares had risen by 139.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.9%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $18.00 
This summary was machine generated from LSEG data February 29 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.20          -0.02          Beat
 Sep. 30 2023      -0.19          -0.18          Beat
 Jun. 30 2023      -0.24          -0.14          Beat
 Mar. 31 2023      -0.32          -0.15          Beat